Argireline Dosage Calculator

Argireline Pharmacokinetics

Argireline Dosing Protocol

Note: Topical anti-wrinkle peptide also known as Acetyl Hexapeptide-3 and Acetyl Hexapeptide-8 (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, MW 889 Da). Developed by Lipotec (now part of Lubrizol) and marketed under the trade name Argireline. Typically formulated in topical serums and creams at 5-10% concentration. The dosing tiers above reflect approximate mg of active peptide per topical application. Clinical studies using 10% formulations report wrinkle depth reductions of 17-49% over 4 weeks of twice-daily application. Apply to clean, dry skin on expression-line areas (forehead, crow's feet, glabella, periorbital region) before moisturizer. CAS number: 616204-22-9.

About Argireline

Argireline (Acetyl Hexapeptide-8, formerly Acetyl Hexapeptide-3) is a synthetic six-amino-acid peptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, designed to reduce the appearance of expression wrinkles through a mechanism analogous to botulinum toxin — but applied topically rather than injected. The hexapeptide sequence is modeled after the N-terminal domain of SNAP-25 (Synaptosomal-Associated Protein of 25 kDa), specifically residues 12-17, which participate in the assembly of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor) complex at neuromuscular junctions. By competing with endogenous SNAP-25 for binding to VAMP (vesicle-associated membrane protein), Argireline destabilizes the ternary SNARE complex that is required for calcium-dependent exocytosis of acetylcholine. This reduces neurotransmitter release at the neuromuscular junction, attenuating the repeated muscle contractions that form dynamic facial wrinkles such as forehead furrows, crow's feet, and frown lines. Unlike botulinum toxin type A, which irreversibly cleaves SNAP-25 through proteolytic action, Argireline acts as a competitive inhibitor — it modulates rather than paralyzes muscle contraction, preserving natural facial expressions while softening expression lines. The original 2002 study by Blanes-Mira et al. demonstrated that a 10% Argireline emulsion reduced wrinkle depth by up to 30% after 30 days of treatment in healthy women volunteers. A subsequent randomized, placebo-controlled study in 60 Chinese subjects showed total anti-wrinkle efficacy of 48.9% in the Argireline group versus 0% in placebo, with statistically significant reductions in all roughness parameters (p < 0.01) after 4 weeks of twice-daily application. However, other studies have produced mixed results — a 2023 double-blind study with 19 subjects found no statistically significant wrinkle reduction compared to control, and the blepharospasm pilot trial using 0.005% topical AH-8 showed trends favoring treatment but did not reach statistical significance. The primary limitation of Argireline is skin penetration: as a hydrophilic peptide (MW 889 Da), it struggles to cross the lipophilic stratum corneum. In vitro penetration studies show only 0.22% of applied peptide is retained in the human stratum corneum, with approximately 0.01% reaching the epidermis and no detectable amounts in the dermis. Advanced delivery systems including multiple water-in-oil-in-water emulsions, liposomes, and microneedle patches are being explored to improve dermal bioavailability. Argireline is classified as a cosmeceutical ingredient and is not FDA-approved for any medical indication. The Cosmetic Ingredient Review (CIR) Expert Panel has assessed acetyl hexapeptide-8 and confirmed its safety in cosmetic formulations.

Frequently Asked Questions